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PHOTOALLERGY AND PHOTOCROSS-SENSITIVITY
TO PHENERGAN*
STEPHAN EPSTEIN, M.D. AND RICHARD J. ROWE, M.D.
Photosensitivity to phenothiazine derivatives, such as Phenergan® and
chiorpromazine, has been recognized for several years (Tzank et al. (1), Sidi
et al. (2), Schulz et at. (3), Kimming (4), John Epstein et at. (5)). The following
is a report of a case of photoallergy to Phenergan®, with investigation of its
contact and photocontact sensitivities.
Report of Case
The patient, a white male, aged 58 years, was first seen at the Clinic on 10—24—55. Six
weeks previously following a fishing trip, he had developed a vesicular dermatitis between
fingers of his right hand, which was considered a poison ivy dermatitis. He was treated by
his family physician on 9—26—55 with a mild lotion, and with Phenergan® orally and was
benefited; subsequently he became worse, the dermatitis spread to the face and the other
hand; finally a papular eruption appeared all over the chest and arms. Treatment with oral
Phenergan® was continued by the patient until 4—18—56. When he returned on 5—8—56 he
stated that the exposed parts of face, neck, arms and hands never cleared up completely.
Exposure to the sun made his face itch and burn. At that time he had a chronic dermatitis
very suggestive of a photosensitivity dermatitis, and photosensitivity from Phenergan®
was suspected. A biopsy specimen from the involved skin showed the following (Dr. Her-
mann Pinkus): "Considerable acanthosis with somewhat irregular rete ridges, hypergranu-
losis and hyperkeratosis with only traces of parakeratosis. The papillae show increased
vascularity, and in the upper corium there is considerable lvmphocytic infiltrate. There is
also considerable destruction of elastic fibers, indicating chronieity. In short, there are the
general features of lichenified eezematous dermatitis."
His dermatitis improved gradually following the elimination of Phenergan® and avoid-
ance of sunlight, and somewhat faster after he received chloroquine. In January 1957 his
skin was practically normal. Sun did not seem to bother him any longer.
Test for Light and Contact Sensitivitie.s
Tests for increased light sensitivity were performed with unfiltered ultra-
violet radiation by direct contact with a water-cooled mercury arc lamp
(Kromayer lamp); they showed an increased sunburn reaction. Exposure to 10
minutes of "filtered ultraviolet light" f produced a mild erythema after 24 hours.
Even twice the amount has never elicited a reaction in normal individuals in
our experience.
Patch tests were performed with Phenergan® and ch1orpromazine at different
times. To begin with, patch tests with 2 % Phenergan® were positive only after
48 hours, but at later dates patch tests even with creams containing only 0.2 %
Received for publication May 20, 1957.
* From the Department of Dermatology, Marshfield Clinic, Marshfield, Wisconsin.
t The term "filtered ultraviolet light" in this paper means ultraviolet irradiation from
a Kromayer lamp filtered through Corning Filter No. 597; this filter eliminates ultraviolet
radiation below 3100 A.
Trade names for chlorpromazine are Thorazine® in this country, and Megaphen® and
Largactil® in Europe.
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and 0.02 % Phenergan® were positive within 24 hours. Patch tests with chior-
promazine ointment (5 % and 1 %) were always negative, with one exception:
One patch test with 5% chlorpromazine, performed several months after the first series
of tests showed a positive reaction after 5 days, whereas the original test with the same
ointment, as well as subsequent patch tests with 1% chiorpromazine, were negative.
Photopatch tests were carried out repeatedly with Phenergan® and chiorpro-
mazine: 5 minutes of "filtered ultraviolet light" were applied 24 hours after the
patch tests had been done. Only in the first series of tests could the light be
applied before the Phenergan® patch test had become positive; because later on
the Phenergan® patch test already showed a reaction within 24 hours. The results
of the photopatch tests were as follows:
Photopatch tests with 2 % Phenergan® cream showed a definitely, though only
moderatly increased reaction compared to the plain patch test with Phenergan®.
A 5 % Thorazine® cream gave a negative patch test but produced an infiltrated
dermatitis at the site of a photopatch test (see fig. 1 and 2). Repetition of the
experiments with 0.2 % and 0.02 % Phenergan® cream and 1 % Thorazine® cream
gave analogous results. Controls on normal individuals with the same patch and
photopatch tests were negative.
A biopsy specimen from the first photopatch test to Phenergan®, taken 72
hours after application of the cream, and 48 hours after the subsequent irradia-
tion with "filtered ultraviolet light" showed the following (Dr. Hermann Pinkus):
"Mild epidermal thickening without changes of the granular or horny layers.
The upper corium contains a very heavy peiivascular infiltrate, not only of
FIG. 1
PATCH TESTS (after 72 hours)
Phenergan positive (left) Thorazine negative (right)
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Fin. 2
PHOTOPATCH TESTS
Phenergan positive (left), somewhat more severe than plain patch test of figure 1 (left).
Thorazine strongly positive reaction (right). Compare with negative plain patch test of
figure 1 (right).
lymphocytes, but larger mononuclear cells as well, but no eosinophiles. There are
several mitoses in connective tissue cells. The changes in the test site have some
similarity to polymorphous light eruption."
Discussion and Commenis
Our patient suffered from a dermatitis due to Phenergan® sensitivity and
photosensitivity, superimposed on a dermatitis of unknown origin. The photo-
sensitivity was induced by oral administration of the drug; at no time had the
patient used Phenergan® externally. A short period of elimination of Phenergan®
during the early stage was followed by improvement, and resumption of this
drug by aggravation. Patch tests and photopatch tests demonstrated that the
patient apparently was contact-sensitive to Phenergan® only, but photoallergic
both to Phenergan® and chlorpromazine.
Tests for photosensitivity suggested increased sensitivity to ultraviolet light,
and also to long wave ultraviolet. This agrees with the findings of Sidi ci al
(2), and Schulz et al (3).
In photosensitivity one must distinguish between phototoxic and photoallergic
mechanisims. Phototoxicity, also called primary photosensitivity, refers to those
non-allergic phenomena which can be produced at will in humans and animals,
providing enough of the drug and proper rays are used. Phototoxic phenomena
include the photodynamic reactions in the strict sense, and also that form of
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such as the phototoxic reaction from sulfanilamide. If an adequate dose of this
drug is injected intradermally, and followed by an erythema-producing dose of
ultraviolet, every tested person will respond with an increased sunburn reaction
at the site of the injection (S. Epstein (6), Burckhardt (7)).
Photoallergic reactions, on the contrary, are not normal, obligatory reactions;
they occur only in a certain number of individuals. In experimental photosensi-
tivity to sulfanilamide, it has been proven that the photoallergic response occur-
red only in some of the tested persons, and was different in character from the
phototoxic reaction. The photoallergic response appeared only after an incu-
bation period of about 10 days; but once a person had become photoallergic, the
reaction regularly could be produced within 24 hours; in short the photoallergic
phenomenon fulfilled all the requirements for an allergic contact reaction.
It seems that in sensitivity to phenothiazine derivatives such as Phenergan®
and chiorpromazine, also both phototoxic and photoallergic reactions are en-
countered.
Schulz, Wiskemann and Wulf (3) have shown that almost all tested pheno-
thiazine derivatives are phototoxic substancs; they will produce positive skin
reactions if the drug and light are applied in suitable quantities. The only drug,
however, which actually in all their tests on patients, as well as on normal con-
trols, produced such reactions was chiorpromazine. John Epstein, Brunsting,
Peterson and Schwartz (5a) also demonstrated the phototoxic effect of chlor-
promazine.
Yet it seems doubtful that this phototoxic reaction could explain the increased
clinical and experimental light sensitivity in all cases. In our patient, the light
tests were carried out about three weeks after the oral use of Phenergan® had
been discontinued. The amount of Phenergan® present in the skin of the patient
would appear insufficient for a phototoxic reaction. On the other hand, a photo-
allergic mechanism alone, would hardly explain the general photosensitivity,
because the tests with light alone produced only an increased erythema, and
not an eczematous reaction. This question needs more study.
There is a disagreement regarding the wave lengths eliciting the phototoxic
reactions. Cahn and Levy (8), and John Epstein and his collaborators (5),
consider ultraviolet below 3100 A responsible. But according to Schulz, Wiske-
mann and Wulf (3) the phototoxic reaction to chlorpromazine is most pro-
nounced when ultraviolet longer than 3200 A is used. In our case the photoal-
lergic reactions to Phenergan® and chlorpromazine were elicited by ultraviolet
longer than 3200 A. Yet, as Schulz et al (5) have noted, the absorption maxima
of chlorpromazine are between 2500 and 2600 A, and 3000 and 3100 A. Phenergan
Hydrochloride® * has absorption maxima of 2035 and 2520 A, a minor peak at
2980 A, and practically no absorption beyond 3350 A. All these data refer to the
pure chemicals. Phenergan®, as well as chlorpromazine, and other phenothiazine
derivatives, discolor on exposure to light; obviously the absorption spectra of the
oxidation and decomposition products of these chemicals, as they occur in living
* Personal communication from Mr. Frank E. Hamerslag, Wyeth Institute for Medical
Research. Philadelphia.
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tissues and biological fluids are different, and apparently have not been deter-
mined, as far as we could ascertain.
The positive reactions to photopatch tests with phenothiazine derivatives
leave no doubt that in certain cases of photosensitivity to these drugs a photo-
allergic mechanism is involved. Schulz, Wiskemann and Wulf (5) were the first
to emphasize the photoallergic nature of their cases 1 and 2 of chiorpromazine
sensitivity, and compared the mechanism to the photoallergic reactions from
sulfanilamide previously demonstrated by S. Epstein (6) and by Burckhardt (7).
Burckhardt (9) also reported two cases of dermatitis from chiorpromazine with
a photoallergic component. The role of photoallergy in contact dermatitis re-
cently has been reviewed by G. Rajka (10).
Mechanism of Photoaliergy to Phener gan® andChiorpromazine
By no means all, perhaps even only a few cases of photosensitivity from
phenothiazine derivatives, are based on photoallergy. According to Burckhardt
(9) it seems probable that light activates chiorpromazine in the skin. He con-
siders it possible that a photochemical process produces an oxidation product
with special antigenic properties, similar to photosensitivity from sulfanilamide.
That such a mechanism is likely, recently has been shown by K. Schwarz and
M. Speck (1 la). These authors were able to produce photoallergy to sulfanilamide
in guinea pigs. Their experiments demonstrated that oxidation products of
sulfanilamide play a role in this process because it is possible to sensitize guinea
pigs with these oxidation products (hydroxylamino compounds of sulfanilamide),
and afterwards to provoke a reaction by exposure to sulfanilamide and light
and vice versa. They were also able to demonstrate hypersensitivity to these
oxidation products without exposure to light in a patient who suffered from
photoallergy to sulfanilamide. Therefore, it seems likely in photoallergy to
sulfanilamide that light produces oxidation products which are the real allergens
in these cases (lib).
A peculiarity of photoallergy to phenothiazine derivatives is the fact that
many of these patients exhibit a double sensitivity, a plain contact sensitivity
against Phenergan® or chlorpromazine itself, and a photocontact sensitivity to
a presumed oxidation or decomposition product of these drugs formed in the
skin. Observations by Tzank et al (1), Sidi et al (2), Schulz et al (3), Burckhardt
(9), as well as our case, showed allergic contact sensitivity to Phenergan® or
chlorpromazine, respectively. This demonstration of the allergic contact sensi-
tivity to the phenothiazine derivative apparently obscured the photoallergic
angle; neither Tzank nor Sidi investigated this aspect. The photoallergic reaction
to chlorpromazine, first reported by Schulz and his coworkers apparently is an
allergic response additional to, and independent of, the plain contact sensitivity
to the drug. This is suggested by the following:
1) Contact sensitivity to chlorpromazine and Phenergan® exists without
accompanying photosensitivity (Lewis and Sawicky (12)).
2) In other photoallergic dermatoses, e. g. from sulfanilamides, perfumes,
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sunprotective agents (Sams (13)), only a photoallergic sensitivity is present,
but no contact sensitivity to the causative chemical without irradiation.
3) The photoallergic reaction in sensitivity to phenothiazine derivatives is of
a much higher degree than the plain contact sensitivity. This is evident by the
comparison of patch tests and photopatch tests, as well as by the clinical ex-
perience. Even where ordinary contact sensitivity to these chemicals is demon-
strated, the internal administration of these drugs usually leads only to an
eruption or aggravation of areas exposed to light; apparently the concentration
of the chemical in the skin is sufficient only for the photoallergic reaction.
4) In cases of crossed photosensitivity between chiorpromazine and Phener-
gan® (Schulz el al) and between Phenergan® and chiorpromazine (our case)
plain contact sensitivity could be demonstrated only to one of the chemicals.
Pholocro&s-Sensitivity
The case presented also seems interesting from the angle of photocross-sensi-
tivity. Cross-sensitivity between various phenothiazine derivatives such as
Phenergan® and chiorpromazine was reported by Sidi, Hincky and Gervais (2).
This cross-sensitivity can be easily understood in the light of the similarity of
the chemical formulas of chlorpromazine and Phenergan® (see table 1).
Photocross-sensitivity between these drugs was first described by Schulz,
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sensitivity to chiorpromazine after external contact. Plain patch tests were
positive only with chiorpromazine. But photopatch tests were also positive with
Phenergan®. Our case showed the same in reverse. The patient had been sensi-
tized by the internal use of Phenergan®. He gave a positive patch test reaction
without light only to Phenergan®, and not to chiorpromazine.
Conclusions
1) In photoallergy to phenothiazine derivatives, such as Phenergan® or chlor-
promazine (Thorazine®), both contact and photocontact sensitivity to these
drugs may be found.
2) The allergen in this photoallergic reaction is different from the original
drug, probably an oxidation or decomposition product.
3) Photocross-sensitivity between Phenergan® and chlorpromazine may exist,
even though plain contact sensitivity (without light) can be demonstrated only
to Phenergan®, and vice versa.
4) Photoallergy plays a role only in some cases of photosensitivity to pheno-
thiazine derivatives.
Summary
A case of photosensitivity to Phenelgan® and chiorpromazine is presented.
Originally contact sensitivity could be demonstrated only to Phenergan®; but
photocross-sensitivity existed at the same time, also to chlorpromazine (Thora-
zine®).
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